West Oak Capital LLC Acquires 2,375 Shares of Pfizer Inc. (NYSE:PFE)

West Oak Capital LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 1,131.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,585 shares of the biopharmaceutical company’s stock after buying an additional 2,375 shares during the quarter. West Oak Capital LLC’s holdings in Pfizer were worth $69,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Strategic Financial Concepts LLC purchased a new stake in Pfizer during the 2nd quarter valued at $38,000. Quest Partners LLC purchased a new stake in shares of Pfizer during the second quarter worth about $570,000. Angeles Wealth Management LLC grew its stake in shares of Pfizer by 24.0% in the second quarter. Angeles Wealth Management LLC now owns 11,580 shares of the biopharmaceutical company’s stock worth $324,000 after purchasing an additional 2,239 shares during the last quarter. AGF Management Ltd. increased its holdings in Pfizer by 6.7% during the 2nd quarter. AGF Management Ltd. now owns 1,223,841 shares of the biopharmaceutical company’s stock valued at $34,243,000 after purchasing an additional 76,464 shares during the period. Finally, HHM Wealth Advisors LLC raised its position in Pfizer by 9.3% during the 2nd quarter. HHM Wealth Advisors LLC now owns 6,311 shares of the biopharmaceutical company’s stock valued at $177,000 after purchasing an additional 538 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Activity

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now owns 10,000 shares of the company’s stock, valued at $282,400. This represents a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on PFE. Guggenheim cut their price objective on Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Citigroup began coverage on shares of Pfizer in a research report on Friday, October 25th. They set a “neutral” rating and a $30.00 price objective on the stock. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Wolfe Research started coverage on shares of Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Pfizer Stock Down 0.5 %

PFE stock traded down $0.13 on Friday, reaching $26.73. 32,556,257 shares of the company traded hands, compared to its average volume of 35,547,035. The firm has a fifty day simple moving average of $26.21 and a 200-day simple moving average of $28.05. The company has a market cap of $151.48 billion, a P/E ratio of 36.12, a price-to-earnings-growth ratio of 0.63 and a beta of 0.64. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company’s revenue was up 31.2% on a year-over-year basis. During the same period last year, the company earned ($0.17) earnings per share. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.43%. The ex-dividend date is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is currently 232.43%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.